key: cord-0777734-00ix5s9f authors: Chiariello, Giovanni A.; Bruno, Piergiorgio; Pavone, Natalia; Calabrese, Maria; D'Avino, Serena; Ferraro, Francesco; Nesta, Marialisa; Farina, Piero; Cammertoni, Federico; Pasquini, Annalisa; Montone, Rocco A.; Montini, Luca; Massetti, Massimo title: Bleeding complications in patients with perioperative COVID-19 infection undergoing cardiac surgery: a single-center matched case-control study date: 2021-11-13 journal: J Cardiothorac Vasc Anesth DOI: 10.1053/j.jvca.2021.11.013 sha: 15455bfc67af3623b62e0949f790b5b23bef7894 doc_id: 777734 cord_uid: 00ix5s9f Objective: Previous studies reported a poor outcome in COVID-19 patients undergoing cardiac surgery. Complications most frequently described were respiratory failure, renal failure and thromboembolic events. In our recent experience we observed a very high incidence of bleeding complications. The purpose of the study was to investigate a possible significant correlation between perioperative COVID-19 infection and hemorrhagic complications compared to non-Covid patients. Design: Single-center, observational, retrospective, matched case-control (1:2) study involving patients who underwent open heart cardiac surgery from February 2020 to March 2021 with positive perioperative diagnosis of COVID-19 infection, matched with patients without COVID-19 infection. Setting: Cardiac Surgery Unit and Intensive Care Unit of an university tertiary center in a metropolitan area. Participants: In the study period 773 patients underwent cardiac surgery on cardiopulmonary bypass (CPB). Among them 23 consecutive patients had perioperative diagnosis of COVID-19 infection (study-group). These patients were compared with 46 corresponding controls (control-group) who matched for age, sex, BMI and STS score. Interventions: Open-heart cardiac surgery on cardiopulmonary bypass (CPB). Measurements and Main results: In the study-group 2 patients (9%) died in the Intensive Care Unit from severe respiratory failure, shock and multiple organ failure. In the study group patients showed a significantly higher incidence of bleeding complications (48% vs 2%, p=0.0001) and cases of surgical reexploration for bleeding (35% vs 2%, p=0.0001), a higher incidence of severe postoperative thrombocytopenia (39% vs 6%, p=0.0007), and a higher need of blood components transfusions (74% vs 30%, p=0.0006). Chest tubes blood loss and surgical hemostasis time (SHT) were markedly prolonged (p=0.02 and p=0.003 respectively). Conclusions: A worrisome increased risk of early and late bleeding complications in COVID-19 patients was observed, and it should be considered when assessing the operative risk. CPB-related inflammatory reaction could exacerbate the deleterious effect of COVID-19 on the coagulation system and likely deviate it towards a hemorrhagic pattern. corresponding controls (control-group) who matched for age, sex, BMI and STS score. Interventions: Open-heart cardiac surgery on cardiopulmonary bypass (CPB). In the study-group 2 patients (9%) died in the Intensive Care Unit from severe respiratory failure, shock and multiple organ failure. In the study group patients showed a significantly higher incidence of bleeding complications (48% vs 2%, p=0.0001) and cases of surgical reexploration for bleeding (35% vs 2%, p=0.0001), a higher incidence of severe postoperative thrombocytopenia (39% vs 6%, p=0.0007), and a higher need of blood components transfusions (74% vs 30%, p=0.0006). Chest tubes blood loss and surgical hemostasis time (SHT) were markedly prolonged (p=0.02 and p=0.003 respectively). A worrisome increased risk of early and late bleeding complications in COVID-19 patients was observed, and it should be considered when assessing the operative risk. CPB-related inflammatory reaction could exacerbate the deleterious effect of COVID-19 on the coagulation system and likely deviate it towards a hemorrhagic pattern. The severe acute respiratory syndrome coronavirus-2 (SARS-COV-2) infection pandemic has markedly affected surgical activity and, in particular, cardiac surgery, worldwide. [1] [2] [3] [4] [5] [6] [7] In many centers, the number of elective surgical cases decreased and patients undergoing surgery that could no longer be delayed, experienced worse outcomes with increased mortality rate and postoperative complications incidence. 1, 5, [7] [8] [9] Among coronavirus disease patients, the most frequent complications included interstitial pneumonia with respiratory failure and acute respiratory distress syndrome (ARDS), acute renal failure and thromboembolic events. 1, [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] However, during surgery in COVID-19 patients, perioperative bleeding was less observed, and has not been thoroughly investigated. Moreover data regarding postoperative bleeding are limited. Main endpoint of the present study was to evaluate whether patients with perioperative COVID-19 who underwent cardiac surgery with cardiopulmonary bypass (CPB) present an increased risk of hemorrhagic complications. More specifically, we considered as "hemorrhagic complications" the rate of surgical reexploration for bleeding (via mediastinal revision through full resternotomy or subxiphoid pericardial drainage); intracranial hemorrhage, and massive hematic hemorrhagic pleural effusion requiring drainage. The mortality rate, the incidence of severe thrombocytopenia, need for blood components transfusions and procoagulant drugs, length of surgical hemostasis time (SHT), blood loss from drains, and length of hospitalization were also analyzed. [12] [13] [14] [15] The aim of this study was to evaluate whether possible inflammatory reactions associated with perioperative COVID-19 infection could contribute to coagulation derangements of CPB and consequently, significantly increase the risk for hemorrhagic complications. The present study was a retrospective, matched (1:2) case-control analysis. Data were acquired from an electronic database of patients undergoing elective, urgent, or emergency cardiac surgery requiring CPB. Patients were operated on in our Cardiac Surgery Unit from February 2020 to March 2021. The study was approved by the Ethics Committee of our University Polyclinic (Approval number: 0051824/20; Protocol ID 3663). Given the retrospective nature of the study and the use of anonymized patient data, requirements for ad-hoc patient consent was waived. Due to the severity of the COVID-19 pandemic, in our region, surgical activity was markedly reduced in most hospitals, and patients with a need for cardiac surgery were compelled to concentrate in a few metropolitan centers, including our Polyclinic. Regardless, in our center an overall reduction of 87 cardiac surgery cases from 2019 to 2020 was recorded. As a regional reference center for COVID-19 care, in the study period, this hospital admitted more than 4800 COVID-19 patients (more than 450 of these patients were hospitalized in the Intensive Care Unit). Except for patients with type A aortic dissection, the surgical indication of COVID-19 patients was, in all instances, validated by the internal Institutional Heart Team and was deemed urgent and to delayable (due to unstable angina or chest pain, heart failure, endocarditis, large aneurysm or rapid aneurysmal growth). Diagnosis of SARS-CoV-2 infection was confirmed via positive throat swab test and Real-Time Polymerase Chain Reaction assay (RT-PCR), which were routinely performed at prehospitalization, on admission and daily during the postoperative course. On admission, data regarding patient's medical history were carefully collected. Chest Xray and chest computed tomography scan were performed when indicated. Personal protective equipment was provided to medical and paramedical health workers, and care staff was limited to essential professionals. Orotracheal intubation was mostly performed In the postoperative period patients were mechanically ventilated using a volume controlled ventilator and extubated, usually 6-8 hours after surgery, in the absence of complications, after having reached satisfactory levels for blood gases in spontaneous breathing and adequate lung ventilation, as documented by chest X-ray. During the postoperative course, red cell transfusion was administered when hemoglobin levels reached 6-7 g/dL and hematocrit was at 22-24%. Platelets were transfused in patients with bleeding manifestations when the platelet count (PLTs) decreased to 80-100.000/ μL. To improve hemostasis and increase filling pressure, fresh frozen plasma (FFP) was administered, when deemed necessary. Mediastinal reexploration for bleeding was considered indicated in cases wherein the rate of blood loss was > 300-400 mL for one hour or > 200-300 mL during the subsequent hours. Hemodynamic instability and hypotension refractory to medical therapy reinforced the indication for mediastinal revision. In addition to the primary and secondary endpoints previously described, attempts were made to indirectly quantify the time taken by surgical maneuvers to achieve hemostasis (SHT, Surgical Hemostasis Time). For this purpose, the time interval (in minutes) from the end of CBP (protamine administration) and the beginning of sternal synthesis sternal closure was retrospectively evaluated, which are time intervals routinely recorded by the anesthesiologist. Patient group matching was based on age (within ± 3 years), sex, body mass index (BMI, within 2 points) and STS (Society of Thoracic Surgeons) score (within 2 points). When multiple control candidates met the core matching criteria, the choice was based on the date of cardiac surgery. The investigators were blinded to case outcomes during matching. The Kolmogorov-Smirnov test was used to evaluate the distribution of variables. Data with non-normal distribution were assessed using the Mann-Whitney U test, and expressed as median and selected centile (25 th -75 th ). Data with a normal distribution were assessed using the Student's t test. Categorical variables were expressed as proportions, and compared using the chi-squared test or Fisher's exact test, as appropriate. Differences with p=< 0.05 were considered to be statistically significant. The crude odds ratio (OR) and corresponding 95% confidence interval (CI) were calculated for each clinically relevant In the postoperative period patients were mechanically ventilated using a volume controlled ventilator and extubated, usually 6-8 hours after surgery, in the absence of complications, after having reached satisfactory levels for blood gases in spontaneous breathing and adequate lung ventilation, supported by X-ray documentation. COVID-19 group patients were compared with 46 corresponding controls with no history or evidence of COVID-19 (baseline characteristics are summarized in Table 1 ). There were no significant between-cohort differences in terms of preoperative characteristics (Table 1 ). In both the groups, three (13%) surgeries were performed on an urgent-emergent basis (type A aortic dissection). STS score for morbidity and mortality was comparable (11 ± 6.9% vs 8.1 ± 5.8, p=0. 3) . CBP time in the study group was 152 ± 79 minutes (vs 130 ± 45, p=0.08), and aortic cross-clamping time was 106 ± 36 minutes (vs 86 ± 27 minutes, p=0.07). SHT was significantly prolonged in the study-group (81 ± 56 vs 64 ± 45 minutes, p=0.0003). (Table 1) Postoperative data are summarized in Table 2 . In the study-group, severe respiratory failure was observed in 6 (26%) patients, two (9%) of whom died from ARDS, cardiovascular shock and multiple organ failure. Bleeding complications occurred in 11 (48%) patients. In 8 (35%) patients, surgical reexploration for bleeding was required, four of whom underwent reoperation at least once for late (after the postoperative day six) hematic hemorrhagic pericardial effusion and cardiac tamponade (Fig.1) . Six patients were reoperated on during their in-hospital postoperative course, and two were urgently (Table 3) . The COVID-19 pandemic and its burden on national health systems has severely impacted services in many areas of medical care. [2] [3] [4] In addition, in many cardiothoracic surgery centers, a severe reduction of operated cases has been observed. 1,4,7-10 COVID-19 syndrome, putatively caused by coronavirus-2, is frequently characterized by acute respiratory failure with radiological signs of interstitial pneumonia, ground glass opacities and/or bilateral patchy shadowing. In some instances, ARDS and shock may also occur. 11 A few studies investigating the clinical outcomes of COVID-19 patients undergone undergoing surgery, reported increased morbidity and mortality. 1, [8] [9] [10] In nine COVID-19 patients undergoing cardiac surgery, Yates et al 1 reported a 44% mortality rate mainly due to severe respiratory failure. SARS-CoV-2 is a pleiotropic virus that causes several different clinical syndromes and changes in laboratory parameters, including thrombocytopenia, lymphocytopenia and a prolonged PT. [10] [11] In addition to respiratory and renal complications, COVID-19 patients may develop coagulation disorders. An increased risk for thromboembolic events has also been documented. [10] [11] However little is known about the risk for perioperative bleeding complications in COVID-19 patients undergoing cardiac surgery. In our study, we observed a marked increase in the incidence of postoperative bleeding complications compared with that noted in non-COVID-19 patients. In our Unit, during the same period, the rate of overall surgical reexplorations for bleeding in non-Covid patients undergone CPB was 4% (30 out of 750 patients) consistent with previously reported results, [12] [13] [14] [15] which was markedly lower than the rate of surgical reexplorations in the studygroup . Among patients with perioperative COVID-19, we observed a high rate of surgical reexploration due to bleeding, with one case of intracranial hemorrhage, two cases of massive hematic hemorrhagic pleural effusion, prolonged hemostasis time (i.e. SHT), conspicuous and prolonged blood loss from drains, and extensive need for blood component transfusions and procoagulant drugs. The pathophysiological mechanisms responsible for the observed postoperative ARDS and multiple organ failure. [19] [20] [21] [22] [23] [24] ( Fig. 2) . A similar mechanism has been described for intracranial hemorrhagic complications occurring spontaneously or after a biopsy procedure, [25] [26] [27] [28] and is likely to occur with any form of bleeding during COVID-19. Furthermore, endothelial damage and diffuse bleeding could lead to thrombocytopenia, consumption of coagulation factors and fibrinolysis, with a possible clinical evolution progressing to acute Disseminated Intravascular Coagulation (DIC), thus aggravating hemorrhagic complications. 29 Moreover, a direct virus-mediated thrombocytopenia has been widely described. 11, 30 In a multicentric analysis of 1099 patients with laboratory-confirmed COVID-19, Guan WJ et al, 11 reported a thrombocytopenia rate of 36.2%. In this vicious cycle, the inflammatory storm with endothelial damage, associated with thrombocytopenia and possible fibrinolysis may explain and justify the observed incidence of late bleeding events (Fig. 2) . The observed significant increase of bleeding complications among COVID-19 patients undergoing cardiac surgery with CPB seems to support the hypotheses described. In this study all patients underwent CPB and, in contrast to that reported in other studies, 1,5,7-10 bleeding was the most frequently encountered complication. The most likely pathophysiological mechanism is, in addition to surgical trauma, CPB-related inflammatory reaction, interstitial edema, heparinization, hemodilution, hemolysis and coagulation factor consumption, which may have contributed to precipitating postoperative hemorrhagic complications (Fig. 2) . CPB could exacerbate the deleterious effect of COVID-19 on the coagulation system, leading to its disruption and a deregulation trend toward a hemorrhagic pattern. For these reasons, patients with perioperative COVID-19 undergoing cardiac surgery appear to be more susceptible to postoperative bleeding requiring mediastinal surgical revision and a high number of blood component transfusions. We observed an increased hemorrhagic risk not only in patients with active COVID-19 at the time of surgery or early postoperatively, but also in those with healed infection before the operation, thus suggesting a possible persistent hyper-inflammatory response even after the resolution of COVID-19. Despite the introduction of vaccines, the problem of global disease spread does not appear to be resolved. In fact, a new increase in infections has recently been observed in Europe and worldwide, and COVID-19 is still considered to be a severe comorbidity among cardiac surgery patients. [31] [32] [33] Based on our experience, it appears that the high risk for perioperative bleeding is associated not only with emergency surgery, such as aortic dissection, but also with elective surgery with no additional preoperative risk factors. Patients with perioperative COVID-19 undergoing cardiac surgery experience a poor outcome with a high rate of complications, including early and late postoperative bleeding. The aim of this study was to provide our experience promptly. We are aware that the relatively small number of patients in this initial retrospective series, the possible relative inaccuracy of certain parameters such as SHT and the lack of definitive information in the literature to support our conclusions may represent a limitation of the study. Another limitation of our study was that we included patients whose molecular diagnosis of COVID- Furthermore, the present study was carried out during the acute phase of COVID-19 outbreak in Italy. Therefore, here were no formal hypothesis being implemented to drive the sample size calculation and we involved the maximum number of patients who met the inclusion criteria during this critical period. However, given that our observations appear to indicate a significantly increased risk for postoperative complications, this increased risk should be taken into consideration when assessing the operative risk of for patients with a perioperative diagnosis of COVID-19. Funding source: none declared angiotensin-converting enzyme II receptor. DIC: disseminated intravascular coagulation. (References 11-30) Table 1 . Patients characteristics and operative data. Acute renal failure n (%) 2 (9) 0 (0) -Hemodialysis n (%) 1 (4) 0 (0) -Hospital stay, (mean±SD) days 17 ± 2.5 9.2 ± 4.7 * 0.01 SD: standard deviation. APTT: Activated partial thromboplastin time *: p= < 0.05; **: tranexamic acid, desmopressin, and fibrinogen Outcome of patients diagnosed with COVID-19 in the early postoperative period following cardiac surgery Surgery at the time of COVID-19 pandemic: initial evidence of safe practice Thoracic surgery during the coronavirus disease 2019 (COVID-19 COVID-19 and coronary artery disease: selective and collaborative use of resources during public health crisis SARS-CoV-2 and COVID-19: facing the pandemic together as citizens and cardiovascular practitioners Cardiac surgery in patients with confirmed COVID-19 infection: Early experience Managements of 13 emergency cardiac surgeries under COVID-19 pandemic in a Sentinel Hospital Cardiac surgery practice during the COVID-19 outbreak: a multicenter national survey Cardiac surgery outcomes in patients with coronavirus disease 2019 (COVID-19):a case series report Perioperative management of COVID-19 patients undergoing cardiac surgery with cardiopulmonary bypass Clinical characteristics of coronavirus disease 2019 in China Planned versus unplanned reexplorations for bleeding: a comparison of morbidity and mortality Estimating the risk of complications related to re-exploration for bleeding after adult cardiac surgery: a systematic review and metaanalysis for the Surgical and Clinical Outcome Research (SCORE) group. Major Bleeding, transfusions, and anemia: the deadly triad of cardiac surgery Surgical drainage of late cardiac tamponade following open heart surgery Weathering the cytokine storm in COVID-19: therapeutic implications The cytokine storm and COVID-19 Myocardial and microvascular injury due to Coronavirus disease 2019 COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options Endothelial cell infection and endothelitis in COVID-19 Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia Coagulopathy in COVID-19 COVID-19 and its implications for thrombosis and anticoagulation Hemorrhagic presentations of COVID-19: Risk factors for mortality Acute hemorrhage after intracerebral biopsy in COVID-19 patients: report of three cases Pathophysiology of SARS-CoV-2 infection in patients with intracerebral hemorrhage Subarachnoid hemorrhage and COVID-19: association or coincidence? Anesthetic Management of Patients Undergoing Aortic Dissection Repair With Suspected Severe Acute Respiratory Syndrome Coronavirus Disease 2019 (COVID-19) Infection Mechanism of thrombocytopenia in COVID-19 patients Impact of COVID-19 pandemic on the Italian humanitarian congenital cardiac surgery activity: what no one tells you COVID-19 and cardiac surgery: the perspective from United Kingdom Perioperative cardiac research considerations during the Coronavirus Disease 2019 (COVID-19) pandemic Figure Legends Acknowledgments: Thank you to Prof. Massimo Fantoni and Dr. Federica Balducci.A very special thanks to Dr. Serena D'Avino and Dr. Francesco Ferraro for their highly valuable contribution to this study.